-+ 0.00%
-+ 0.00%
-+ 0.00%

BRIEF-Definium Therapeutics Phase 3 Voyage Study Of DT120 ODT Met Primary & Key Secondary Efficacy Endpoints

Reuters·08/12/2026 11:00:01

Please log in to view news